National Institute for Health and Care Excellence (NICE)
About one in 5 women in this age group has used GLP-1 medications, the highest rate of any age group
Notably, a 2020 clinical trial involving patients with nonalcoholic steatohepatitis (NASH) revealed a 15% incidence of tumors (benign, malignant, or unspecified) (35/239) among those administered semaglutide, compared to 8% (6/80) in the control group [108]
Inform patients that management requires implementing a long-term plan, setting realistic weight goals, and overcoming ongoing challenges of weight maintenance
A patient losing 30 pounds with semaglutide over 12 months would pay approximately $200-250 per pound lost with compounded versions, while a Contrave patient losing 15 pounds would pay approximately $200-300 per pound lost
Are GLP-1 patches better than weight loss injections